RecruitingNot ApplicableNCT06543537

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer


Sponsor

Dana-Farber Cancer Institute

Enrollment

112 participants

Start Date

Jan 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a communication tool called CASI (Collaborative Agenda-setting Intervention) to help patients with advanced ovarian cancer and their care teams have better, more structured conversations during chemotherapy visits. **You may be eligible if...** - You are 18 or older with advanced ovarian cancer (stage III, stage IV, or recurrent) - You are currently undergoing chemotherapy - You can communicate in English - You are willing to be audio recorded - Caregivers (family, partners, or close friends) may also be eligible to participate alongside the patient **You may NOT be eligible if...** - You cannot communicate in English - You are not receiving care from a participating medical team at the study site Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALCollaborative Agenda-Setting Intervention

A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.


Locations(1)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06543537


Related Trials